SAMSARA BIOCAPITAL, LLC
PALO ALTO, CA · CIK 1744967 · 13F filing filed 2021-08-17
SEC-registered investment adviser since 2018 · limited liability company
- Assets managed$2.2bn
- Staff31 · 22 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds3 · $2.3bn gross assets
- Websitesamsaracap.com
- Form ADV · 2026-06-26SEC adviser record
- Kindventure
- Others nearbyPalo Alto, CA
As an employer
- Private fundsventure capital 3
US visa salary filings
- Filings FY20242
- Median salary offered$187,500
- Middle half$181,250 – $193,750
- Job titles1
| Job title | Filings | Median |
|---|---|---|
| Senior AssociatePalo Alto, CA | 2 | $187,500 |
Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Samsara BioCapital, LLC.
$760.8m
reported value
+53.2% vs Q1 2021
48positions
72.6%in top 10
7 new
2 added
11 reduced
1 sold out
vs Q1 2021
Options: 2 call positions ($49.3m notional), 0 put positions (— notional) – listed below, not included above.
Holdings, Q2 2021
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| GRAPHITE BIO INC GRPH | $228.4m30.02% | New |
| NKARTA INC NKTX | $64.5m8.48% | Unchanged |
| CHINOOK THERAPEUTICS INC ADRO | $44.7m5.88% | Unchanged |
| INSTIL BIO INC COM | $41.4m5.45% | Added +591.4k |
| FORMA THERAPEUTICS HLDGS INC SHS | $39.0m5.12% | Unchanged |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $34.1m4.49% | New |
| SUTRO BIOPHARMA INC COM | $31.1m4.09% | Unchanged |
| RECURSION PHARMACEUTICALS IN RXRX | $28.3m3.72% | New |
| RAIN ONCOLOGY INC COM | $25.4m3.34% | New |
| JANUX THERAPEUTICS INC JANX | $15.2m1.99% | New |
| SPRINGWORKS THERAPEUTICS INC SWTX | $14.0m1.84% | Unchanged |
| ACLARIS THERAPEUTICS INC ACRS | $13.9m1.83% | Reduced -228.4k |
| IVERIC BIO INC OPHT | $13.4m1.76% | Reduced -247.1k |
| INTERCEPT PHARMACEUTICALS IN ICPT | $12.8m1.68% | Unchanged |
| ELEVATION ONCOLOGY INC COM | $12.7m1.66% | New |
| ALLAKOS INC ALLKG | $12.5m1.64% | Unchanged |
| BOLT BIOTHERAPEUTICS INC COM | $11.4m1.50% | Unchanged |
| SYROS PHARMACEUTICALS INC SYRS | $10.6m1.39% | Unchanged |
| VIRACTA THERAPEUTICS INC SNSS | $8.1m1.06% | Reduced -120.6k |
| VERONA PHARMA PLC VRNA | $7.3m0.96% | Unchanged |
| DECIBEL THERAPEUTICS INC COM | $7.1m0.93% | Unchanged |
| NOVAVAX INC NVAX | $6.4m0.84% | Unchanged |
| AEGLEA BIOTHERAPEUTICS INC AGLE | $6.2m0.81% | Unchanged |
| RHYTHM PHARMACEUTICALS INC RYTM | $5.9m0.77% | Added +99.2k |
| BCTG ACQUISITION CORP COM | $5.7m0.75% | Unchanged |
| JIYA ACQUISITION CORP COM CL A | $5.0m0.66% | Unchanged |
| DAY ONE BIOPHARMACEUTICALS I COM | $4.6m0.61% | New |
| EQUILLIUM INC EQ | $4.3m0.57% | Reduced -26.2k |
| EYEPOINT PHARMACEUTICALS INC EYPT | $4.0m0.53% | Unchanged |
| AVADEL PHARMACEUTICALS PLC SPONSORED ADR | $3.7m0.49% | Unchanged |
| TERNS PHARMACEUTICALS INC COM | $3.5m0.47% | Reduced -208.5k |
| ALBIREO PHARMA INC BIOD | $3.5m0.46% | Unchanged |
| ATRECA INC BCEL | $3.4m0.44% | Unchanged |
| KALA PHARMACEUTICALS INC COM | $3.2m0.42% | Unchanged |
| BCLS ACQUISITION CORP COM CL A | $3.2m0.42% | Unchanged |
| CONSONANCE HFW ACQUISITION C UNIT 99/99/9999 | $3.1m0.41% | Unchanged |
| IMMUNOCORE HLDGS PLC IMCR | $2.5m0.33% | Reduced -16.0k |
| ALPINE IMMUNE SCIENCES INC NVLS | $2.5m0.33% | Reduced -124.0k |
| ODONATE THERAPEUTICS INC COM | $2.4m0.32% | Unchanged |
| VISTAGEN THERAPEUTICS INC VTGN | $2.3m0.30% | Reduced -1.1m |
| LIFESCI ACQUISITION II CORP COM | $2.0m0.26% | Unchanged |
| KRONOS BIO INC KRON | $1.9m0.25% | Reduced -88.1k |
| ROCKET PHARMACEUTICALS INC RCKT | $1.8m0.24% | Reduced -23.2k |
| ALLOVIR INC COM | $1.6m0.21% | Unchanged |
| BIONTECH SE BNTX | $1.3m0.17% | Reduced -5.0k |
| NGM BIOPHARMACEUTICALS INC NGM | $359.0k0.05% | Unchanged |
| CATABASIS PHARMACEUTICALS IN CATB | $317.0k0.04% | Unchanged |
| AMARIN CORP PLC SPONS ADR NEW | $110.0k0.01% | Unchanged |
Sold out since Q1 2021
| Security | Value then |
|---|---|
| CUREVAC N V CVAC | $8.7m95.3k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| NOVAVAX INC NVAX · Call | $42.2m198.6k shares | Unchanged |
| ALLAKOS INC ALLKG · Call | $7.1m83.0k shares | Unchanged |